Minor effects of green tea catechin supplementation on cardiovascular risk markers in active older people: A randomized controlled trial

Miyazaki, Ryo; Kotani, Kazuhiko; Ayabe, Makoto; Tsuzaki, Kokoro; Shimada, Junko; Sakane, Naoki; Takase, Hideto; Ichikawa, Hiroshi; Yasuda, Yoshikazu; Ishii, Kojiro

doi:10.1111/j.1447-0594.2012.00952.x

Cited by 28 publications

(23 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were observed in some12, 31 but not all previous studies 30, 32. Total/HDL cholesterol reflects the balance between the cholesterol carried by atherogenic and protective lipoproteins 33.…”

Section: Discussionsupporting

confidence: 87%

Tea Consumption and Longitudinal Change in High‐Density Lipoprotein Cholesterol Concentration in Chinese Adults

Huang

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundThe relation between tea consumption and age‐related changes in high‐density lipoprotein cholesterol (HDL‐C) concentrations remains unclear, and longitudinal human data are limited. The aim of current study was to examine the relation between tea intake and longitudinal change in HDL‐C concentrations.Methods and ResultsBaseline (2006) tea consumption was assessed via a questionnaire, and plasma HDL‐C concentrations were measured in 2006, 2008, 2010, and 2012 among 80 182 individuals (49±12 years of age) who did not have cardiovascular diseases or cancer, or did not use cholesterol‐lowering agents both at baseline (2006) and during the follow‐up period (2006–2012). The associations between baseline tea consumption and rate of change in HDL‐C concentrations were examined using generalized estimating equation models. Tea consumption was inversely associated with a decreased rate of HDL‐C concentrations (P‐trend <0.0001) in the fully adjusted model. The adjusted mean difference in the HDL‐C decreased rate was 0.010 (95% confidence interval, 0.008, 0.012) mmol/L per year for tea consumers versus nonconsumers (never or less than once/month group). Interactions between tea consumption and age, sex, lifestyle scores, and metabolic syndrome (all P‐interaction <0.0001) were identified. The associations between greater tea consumption and slower decrease in HDL‐C concentrations were more pronounced in men, individuals aged 60 or older, individuals with a lower lifestyle score, and individuals with metabolic syndrome (all P‐trend <0.0001).ConclusionsTea consumption was associated with slower age‐related decreases in HDL‐C concentrations during 6 years of follow‐up.Clinical Trial Registration URL: http://www.chictr.org. Unique identifier: ChiCTR‐TNRC‐11001489.

show abstract

Section: Discussionsupporting

confidence: 87%

Tea Consumption and Longitudinal Change in High‐Density Lipoprotein Cholesterol Concentration in Chinese Adults

Huang

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

“…Four of the studies were related to catechins ( Table 2 ), and the quality score assigned according to the Jadad scale was around 3–5. Two of the studies were with healthy subjects between 32 and 69 years old [ 37 , 38 ] (sample size 52 and 64 in each one). In regard to the other two studies, one included 52 subjects with early atherosclerosis (mean of 42 years of age) [ 39 ], and the other included 240 subjects with visceral fat-type obesity aged around 25–55 years old [ 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…In the studies with healthy subjects [ 37 , 38 ] and the one in visceral fat-type obesity [ 40 ], catechins were obtained from green and black tea, with doses between 583 mg and 3 g per day during periods between 4 and 14 weeks. The atherosclerotic subjects [ 39 ] were supplemented with 30 mL of epigallocatechin gallate (EGCG)-supplemented olive oil during 4 months.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Phenolic Compounds

et al. 2015

View full text Add to dashboard Cite

The prevalence of cardiovascular diseases (CVD) is rising and is the prime cause of death in all developed countries. Bioactive compounds (BAC) can have a role in CVD prevention and treatment. The aim of this work was to examine the scientific evidence supporting phenolic BAC efficacy in CVD prevention and treatment by a systematic review. Databases utilized were Medline, LILACS and EMBASE, and all randomized controlled trials (RCTs) with prospective, parallel or crossover designs in humans in which the effects of BAC were compared with that of placebo/control were included. Vascular homeostasis, blood pressure, endothelial function, oxidative stress and inflammatory biomarkers were considered as primary outcomes. Cohort, ecological or case-control studies were not included. We selected 72 articles and verified their quality based on the Scottish Intercollegiate Guidelines Network, establishing diverse quality levels of scientific evidence according to two features: the design and bias risk of a study. Moreover, a grade of recommendation was included, depending on evidence strength of antecedents. Evidence shows that certain polyphenols, such as flavonols can be helpful in decreasing CVD risk factors. However, further rigorous evidence is necessary to support the BAC effect on CVD prevention and treatment.

show abstract

“…Six studies focused on non-obese individuals (BMI <25) with a mean age between 28 (Nagao et al 2005) and 60-80 years old (Miyazaki et al 2013). Eight studies included both males and females, four included only males (Nozawa et al 2002;Nagao et al 2005;Takeshita et al 2008;Brown et al 2011) and five focused solely on females (Erba et al 2005;Kajimoto et al 2006;Diepvens et al 2006;Hsu et al 2008;Chen et al 2016).…”

Section: Study Characteristicsmentioning

confidence: 97%

Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans

Momose

Maeda‐Yamamoto

Nabetani

2016

International Journal of Food Sciences and Nutrition

View full text Add to dashboard Cite

We conducted a systematic review of the literature for the ability of green tea epigallocatechin gallate (EGCG) to lower low-density lipoprotein cholesterol (LDL-C). Study subjects were limited to healthy individuals and randomized, controlled trials on human serum lipid levels, especially LDL-C, conducted. A total of 17 trials (n = 1356) met all of the inclusion criteria. According to weighted mean differences for changes from baseline with 95% confidence intervals (CI), 107-856 mg/d of EGCG for 4 to 14 weeks reduced LDL-C by -9.29 mg/dl (95% CI, -12.27 to -6.31). Sub-analysis was performed to compare the EGCG lowering effect on LDL-C between non-obese and obese subjects, EGCG dose, baseline of LDL-C levels, or BMI. We concluded that consumption of green tea EGCG resulted in a significant reduction of LDL-C at any baseline level and any dose between 107 and 856 mg/d, and the effect size was slightly dependent on the baseline lipid level of the subjects.

show abstract

Minor effects of green tea catechin supplementation on cardiovascular risk markers in active older people: A randomized controlled trial

Cited by 28 publications

References 49 publications

Tea Consumption and Longitudinal Change in High‐Density Lipoprotein Cholesterol Concentration in Chinese Adults

Tea Consumption and Longitudinal Change in High‐Density Lipoprotein Cholesterol Concentration in Chinese Adults

A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Phenolic Compounds

Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans

Contact Info

Product

Resources

About